NLM Digital Collections

Search

Start Over Formats Text ✖Remove constraint Formats: Text Collections Health Policy and Services Research ✖Remove constraint Collections: Health Policy and Services Research Subjects United States. Department of Health and Human Services. ✖Remove constraint Subjects: United States. Department of Health and Human Services. Genre Technical Report ✖Remove constraint Genre: Technical Report Copyright Public domain ✖Remove constraint Copyright: Public domain

41. Opioid use in Medicare Part D remains concerning

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Medicare Part D
Opioid-Related Disorders -- epidemiology
Prescription Drug Misuse
Analgesics, Opioid -- economics
Fentanyl -- adverse effects
Prescription Drug Diversion
Humans
United States
United States. Department of Health and Human Services.

42. CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2018
Subject(s):
Durable Medical Equipment -- economics
Insurance, Health, Reimbursement
Medicare -- economics
Skilled Nursing Facilities
Home Care Services -- economics
Insurance Claim Review
Insurance Coverage
Medicaid -- economics
Nursing Homes
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

43. Opioids in Ohio Medicaid: review of extreme use and prescribing

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Inappropriate Prescribing
Medicaid
Opioid-Related Disorders -- epidemiology
Opioid-Related Disorders -- prevention & control
Prescription Drug Misuse
Analgesics, Opioid -- administration & dosage
Humans
Ohio
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

46. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

47. Questionable billing for compounded topical drugs in Medicare Part D

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Dermatologic Agents -- economics
Dermatologic Agents -- therapeutic use
Drug Compounding -- economics
Drug Utilization -- trends
Fraud
Insurance, Health, Reimbursement
Medicare Part D -- economics
Skin Cream -- economics
Administration, Topical
Dermatologic Agents -- adverse effects
Drug Compounding -- standards
Forecasting
Health Expenditures -- trends
Insurance Coverage
Skin Cream -- adverse effects
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

48. FDA should further integrate its review of cybersecurity into the premarket review process for medical devices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Computer Security
Device Approval -- standards
Equipment and Supplies -- standards
Equipment Safety -- standards
Computer Communication Networks -- standards
Guidelines as Topic
Software -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

49. Treatment planning and medication monitoring were lacking for children in foster care receiving psychotropic medication

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Antipsychotic Agents -- therapeutic use
Foster Home Care
Medication Therapy Management
Patient Care Planning
Child
Child Health Services -- standards
Inappropriate Prescribing
Mental Disorders -- drug therapy
Practice Guidelines as Topic
State Government
Humans
United States
United States. Department of Health and Human Services.

50. Medicare payments for clinical diagnostic laboratory tests in 2017: year 4 of baseline data

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Clinical Laboratory Techniques -- economics
Insurance, Health, Reimbursement
Medicare Part B -- economics
Prospective Payment System
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

54. Medicare Advantage appeal outcomes and audit findings raise concerns about service and payment denials

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Health Services Accessibility
Insurance Claim Review -- statistics & numerical data
Insurance Coverage
Insurance, Health, Reimbursement
Medicare Part C
Financial Audit
Insurance Claim Review -- economics
Managed Care Programs
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

55. States follow a common framework in responding to breaches of Medicaid data

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, October 2018
Subject(s):
Computer Security
Fraud -- prevention & control
Medicaid
Federal Government
Health Records, Personal
State Government
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

56. Hospitals reported improved preparedness for emerging infectious diseases after the Ebola outbreak

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, October 2018
Subject(s):
Communicable Disease Control
Disease Outbreaks -- prevention & control
Disease Transmission, Infectious -- prevention & control
Hemorrhagic Fever, Ebola -- epidemiology
Hospitals
Civil Defense
Emergency Medical Services
Inservice Training
Humans
United States
United States. Department of Health and Human Services.
Centers for Disease Control and Prevention (U.S.)

57. Health document submission requirements for tobacco products: (revised)

Publication:
Silver Spring, MD : Center for Tobacco Products, October 2017
Subject(s):
Documentation -- standards
Tobacco Products -- standards
Drug Approval
Health
Terminology as Topic
Tobacco Products -- adverse effects
Tobacco Products -- toxicity
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.

58. Registration and product listing for owners and operators of domestic tobacco product establishments: (revised)

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, December 2017
Subject(s):
Registries -- standards
Tobacco Products -- standards
Manufacturing and Industrial Facilities -- standards
Product Labeling -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.

59. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, February 2018
Subject(s):
Clinical Trials as Topic -- standards
Drug Evaluation -- standards
Urinary Bladder Neoplasms -- drug therapy
Biological Products -- therapeutic use
Chemistry, Pharmaceutical
Mycobacterium bovis
Research Design
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

60. Regulatory classification of pharmaceutical co-crystals

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, February 2018
Subject(s):
Chemistry, Pharmaceutical -- classification
Chemistry, Pharmaceutical -- standards
Crystallization -- classification
Investigational New Drug Application
Biological Availability
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

Refine by:

more »

more »

more »

Current results range from 2010 to 2022